Evaluating biomarkers for infection and inflammation in sepsis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This investigation aims to assess the effectiveness of early biomarkers in identifying patients at risk for poor outcomes in sepsis and septic shock. It focuses on the body's immune response and inflammatory markers that may indicate the severity of infection. Current laboratory parameters like white blood cell count and CRP are commonly used but are not always reliable, prompting the need for better predictive tests. By understanding the host response to infection, the study seeks to improve patient management and treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria for Infected subjects:

* Age 18 years of age or older
* Confirmed or suspected infection

Inclusion Criteria for Control Subjects:

* Age 18 years of age or older
* A non-infectious clinical presentation to include
* Normal white blood cell count ( \> 4,000 and/or \< 12,000)
* Normothermia ( \> 96.5 and/or less 100.4)
* Absence of the following clinical complaints: productive cough, fever, pyuria, rash
* No evidence of acute coronary syndrome

Exclusion Criteria for Control Subjects:

\- Suspected infection

Where it's running

• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Recruiting
• Massachusetts General Hospital
  Boston, Massachusetts, United States Active not recruiting

Study contacts

• Principal investigator: Nathan Shapiro, MD MPH — Beth Israel Deaconess Medical Center
• Study coordinator: Nathan Shapiro, MD MPH
• Email: nshapiro@bidmc.harvard.edu
• Phone: 617-754-2343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

  This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

• Early detection of sepsis-related blood clotting problems in severe burn patients

  This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

  Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

• Neutrophil EMR3 as a biomarker for sepsis in ICU patients

  Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07896018

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

• Multicenter group study of sepsis and ARDS in China

  This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.

  Recruiting at 24 sites Shanghai Zhongshan Hospital · Xiamen, Fujian and 23 other locations · NCT07863908

• Non-invasive hemodynamic guidance for sepsis care on medical wards

  This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.

  Recruiting at 2 sites Regione del Veneto - AULSS n. 7 Pedemontana · Pisa, Pisa and 1 other locations · NCT07863323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.